{"title":"Relative efficacy and safety of mesenchymal stem cells for osteoarthritis: a systematic review and meta-analysis of randomized controlled trials","authors":"Xiaoyuan Tian, Zhenan Qu, Ying Cao, Bocheng Zhang","doi":"10.3389/fendo.2024.1366297","DOIUrl":null,"url":null,"abstract":"The aim of this meta-analysis was to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) for the treatment of knee osteoarthritis (OA). The PubMed, Embase, Cochrane Central Register of Controlled Trials, Scopus and Web of Science databases were searched from inception to May 6, 2024 to identify randomized controlled trials that compared MSCs and placebo or other nonsurgical approaches for treating OA. Two investigators independently searched the literature and extracted data, and conventional meta-analyses were conducted with Review Manager 5.3. The outcomes included pain relief, functional improvement, and risk of adverse events (AEs).A total of 18 articles were included. Overall, MSCs were superior to placebo in terms of relieving pain and improving function at the 12-month follow-up. However, the differences in treatment-related AEs were not significant.MSCs may relieving pain and improving function of OA. The limitations of this study include the high heterogeneity of the included studies. Additionally, the follow-up time in the included studies was relatively short, so more clinical trials are needed to predict the long-term efficacy and safety of MSCs.https://doi.org/10.17605/OSF.IO/5BT6E, identifier CRD42022354824.","PeriodicalId":505784,"journal":{"name":"Frontiers in Endocrinology","volume":" 13","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fendo.2024.1366297","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The aim of this meta-analysis was to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) for the treatment of knee osteoarthritis (OA). The PubMed, Embase, Cochrane Central Register of Controlled Trials, Scopus and Web of Science databases were searched from inception to May 6, 2024 to identify randomized controlled trials that compared MSCs and placebo or other nonsurgical approaches for treating OA. Two investigators independently searched the literature and extracted data, and conventional meta-analyses were conducted with Review Manager 5.3. The outcomes included pain relief, functional improvement, and risk of adverse events (AEs).A total of 18 articles were included. Overall, MSCs were superior to placebo in terms of relieving pain and improving function at the 12-month follow-up. However, the differences in treatment-related AEs were not significant.MSCs may relieving pain and improving function of OA. The limitations of this study include the high heterogeneity of the included studies. Additionally, the follow-up time in the included studies was relatively short, so more clinical trials are needed to predict the long-term efficacy and safety of MSCs.https://doi.org/10.17605/OSF.IO/5BT6E, identifier CRD42022354824.
这项荟萃分析旨在评估间充质干细胞(MSCs)治疗膝骨关节炎(OA)的有效性和安全性。研究人员检索了PubMed、Embase、Cochrane Central Register of Controlled Trials、Scopus和Web of Science等数据库,时间跨度从开始到2024年5月6日,以确定比较间充质干细胞和安慰剂或其他非手术疗法治疗OA的随机对照试验。两名研究人员独立检索文献并提取数据,使用Review Manager 5.3进行常规荟萃分析。结果包括疼痛缓解、功能改善和不良事件(AEs)风险。总体而言,在12个月的随访中,间充质干细胞在缓解疼痛和改善功能方面优于安慰剂。然而,治疗相关的AEs差异并不显著。本研究的局限性包括所纳入研究的高度异质性。此外,纳入研究的随访时间相对较短,因此需要更多的临床试验来预测间充质干细胞的长期疗效和安全性。https://doi.org/10.17605/OSF.IO/5BT6E,标识符为CRD42022354824。